Imperial College London

ProfessorEricAboagye

Faculty of MedicineDepartment of Surgery & Cancer

Professor
 
 
 
//

Contact

 

+44 (0)20 3313 3759eric.aboagye

 
 
//

Assistant

 

Mrs Maureen Francis +44 (0)20 7594 2793

 
//

Location

 

GN1Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sharma:2019:10.1016/j.radonc.2019.09.003,
author = {Sharma, R and Wang, WM and Yusuf, S and Evans, J and Ramaswami, R and Wernig, F and Frilling, A and Mauri, F and Al-Nahhas, A and Aboagye, EO and Barwick, TD},
doi = {10.1016/j.radonc.2019.09.003},
journal = {Radiotherapy and Oncology},
title = {68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours},
url = {http://dx.doi.org/10.1016/j.radonc.2019.09.003},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - PURPOSE: [177Lu]DOTATATE prolongs progression free survival (PFS) in metastatic neuroendocrine tumours (NETs). However, objective response rate is low. This, coupled with long duration of therapy and expense suggest need for better selection. We aim to assess whether baseline [68Ga]DOTATATE-PET/CT parameters, and whether response assessment by PET accurately predicts clinical outcome to [177Lu]DOTATATE. EXPERIMENTAL DESIGN: Retrospective study of patients receiving [177Lu]DOTATATE was conducted. Patients were followed 3-monthly until disease progression. Four [68Ga]DOTATATE-PET parameters (single lesion SUVmax, tumour to spleen and liver SUV ratios, and SUVmax-av using up to five target lesions in multiple organ sites) were determined at baseline and follow-up. The association between these PET parameters either at baseline, or any changes following treatment, and PET response criteria (PERCIST and modified PERCIST) to predict PFS were determined. Patients were followed 3-monthly until disease progression. Response was determined using RECIST 1.1. Baseline SSTR2 expression was assessed and compared with PET parameters. RESULTS: 55 patients with metastatic NETs were identified predominantly small bowel (N=18) and pancreatic (N=8) in origin. 16 were low grade, 15 intermediate and 3 high grade. Response to PRRT (N=47): partial response (PR) 28%, stable disease (SD) 60% progressive disease (PD) 13%. Response to PRRT predicted PFS: PR 71.8months (95%CI: not achieved), SD 29.1months (95%CI: 15.2-43.1), and PD 9.7months (95%CI: 0-21.02). Baseline, single lesion SUVmax predicted both response and PFS with SUV cut-off of 13.0 giving high sensitivity and specificity. Tumoural SUVmax correlated with SSTR2 expression, Spearman's rho - 0.69, p<0.01. CONCLUSIONS: Baseline single lesion SUVmax and SUVmax-av predicts response to [177Lu]DOTATATE. Objective response following PRRT defines a subset of patients with markedly improved PFSBaseline SUVmax 13.0 defines a thre
AU - Sharma,R
AU - Wang,WM
AU - Yusuf,S
AU - Evans,J
AU - Ramaswami,R
AU - Wernig,F
AU - Frilling,A
AU - Mauri,F
AU - Al-Nahhas,A
AU - Aboagye,EO
AU - Barwick,TD
DO - 10.1016/j.radonc.2019.09.003
PY - 2019///
SN - 0167-8140
TI - 68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours
T2 - Radiotherapy and Oncology
UR - http://dx.doi.org/10.1016/j.radonc.2019.09.003
UR - https://www.ncbi.nlm.nih.gov/pubmed/31542317
UR - http://hdl.handle.net/10044/1/74065
ER -